

Kirk R Schultz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2395163/publications.pdf>

Version: 2024-02-01

188
papers

12,667
citations

38720

50
h-index

25770

108
g-index

192
all docs

192
docs citations

192
times ranked

10471
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
2	Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5175-5181.	0.8	643
3	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-47.	2.0	427
4	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	0.6	413
5	Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. <i>Leukemia</i> , 2014, 28, 1467-1471.	3.3	384
6	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
7	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
8	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
9	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2016, 17, 164-173.	5.1	283
10	One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2014, 371, 1685-1694.	13.9	246
11	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	1.3	243
12	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	0.6	228
13	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 589-603.	2.0	228
14	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	0.8	185
15	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1167-1187.	2.0	182
16	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015, 125, 3501-3508.	0.6	177
17	Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. <i>Blood</i> , 2008, 111, 3276-3285.	0.6	143
18	Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. <i>Blood</i> , 2016, 127, 392-399.	0.6	141

#	ARTICLE	IF	CITATIONS
19	Toward Biomarkers for Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 126-137.	2.0	139
20	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	0.8	136
21	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
22	Chronic Graft-Versus-Host Disease (GVHD) in Children. <i>Pediatric Clinics of North America</i> , 2010, 57, 297-322.	0.9	112
23	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	0.8	111
24	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014, 123, 2017-2025.	0.6	109
25	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010, 116, 4007-4015.	0.6	105
26	Combined immunodeficiency associated with homozygous MALT1 mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1458-1462.e7.	1.5	103
27	A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. <i>British Journal of Haematology</i> , 1999, 106, 1027-1032.	1.2	100
28	Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 41-46.	1.0	90
29	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
30	Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1995, 16, 289-95.	1.3	89
31	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018, 32, 2316-2325.	3.3	88
32	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.	0.6	83
33	Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 386-397.	2.0	81
34	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	2.5	81
35	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
36	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 322-328.e10.	1.5	79

#	ARTICLE	IF	CITATIONS
37	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018, 132, 1438-1451.	0.6	78
38	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
39	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 67-73.	2.0	62
40	Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. <i>Blood</i> , 2019, 134, 304-316.	0.6	62
41	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
42	Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high-risk Features of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study Report. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 218-227.	2.0	60
43	Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?. <i>Bone Marrow Transplantation</i> , 2015, 50, 1173-1179.	1.3	59
44	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e100-e111.	2.2	59
45	The Lysosomotropic Amines, Chloroquine and Hydroxychloroquine: A Potentially Novel Therapy for Graft-Versus-Host Disease. <i>Leukemia and Lymphoma</i> , 1997, 24, 201-210.	0.6	58
46	Randomized Trial of Hydroxychloroquine for Newly Diagnosed Chronic Graft-versus-Host Disease in Children: A Children's Oncology Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 84-91.	2.0	56
47	Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. <i>Blood</i> , 2014, 123, 1615-1620.	0.6	56
48	Biomarkers in chronic graft-versus-host disease: quo vadis?. <i>Bone Marrow Transplantation</i> , 2018, 53, 832-837.	1.3	55
49	Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1029-1036.	2.0	53
50	Obstructive lung disease in children after allogeneic bone marrow transplantation: evaluation with high-resolution CT.. <i>American Journal of Roentgenology</i> , 1995, 164, 693-696.	1.0	51
51	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27827.	0.8	50
52	Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. <i>Blood</i> , 2020, 135, 1287-1298.	0.6	49
53	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 780-789.	0.8	48
54	An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India. <i>Cancer</i> , 1993, 72, 282-286.	2.0	47

#	ARTICLE	IF	CITATIONS
55	Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 624-634.	2.0	47
56	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
57	Early and Late Extensive Chronic Graft-versus-Host Disease in Children Is Characterized by Different Th1/Th2 Cytokine Profiles: Findings of the Children's Oncology Group Study ASCT0031. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1804-1813.	2.0	38
58	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 870-881.	2.0	38
59	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37
60	Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S115-S122.	2.0	36
61	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
62	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	2.0	36
63	A population-based study of pediatric anaplastic large cell lymphoma. <i>Cancer</i> , 2002, 94, 1830-1835.	2.0	35
64	Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation. <i>Clinical Immunology</i> , 2016, 168, 1-5.	1.4	35
65	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
66	Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. <i>Medical and Pediatric Oncology</i> , 1997, 29, 16-22.	1.0	32
67	Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 45-51.	0.3	31
68	Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 545-551.	1.3	30
69	Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. <i>Leukemia</i> , 2014, 28, 964-967.	3.3	29
70	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2040-2046.	2.0	29
71	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	0.6	29
72	Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. <i>JAMA Network Open</i> , 2020, 3, e203639.	2.8	27

#	ARTICLE	IF	CITATIONS
73	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. <i>British Journal of Haematology</i> , 2002, 116, 266-272.	1.2	26
74	Severe Combined Immunodeficiency (SCID) in Canadian Children: A National Surveillance Study. <i>Journal of Clinical Immunology</i> , 2013, 33, 1310-1316.	2.0	26
75	Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene. <i>Journal of Clinical Immunology</i> , 2015, 35, 15-21.	2.0	25
76	Molecular and phenotypic diversity of <i>CBL</i>-mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2022, 107, 178-186.	1.7	25
77	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1714-1721.	2.0	24
78	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
79	Biomarkers in chronic graft-versus-host disease. <i>Expert Review of Hematology</i> , 2011, 4, 329-342.	1.0	23
80	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
81	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq1 1o067843143gBT /C		
82	Obstructive lung disease in children after allogeneic bone marrow transplantation. <i>Blood</i> , 1994, 84, 3212-20.	0.6	23
83	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1410-1415.	2.0	22
84	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016, 101, 1267-1274.	1.7	22
85	InÂVivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2173-2179.	2.0	21
86	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
87	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
88	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 363-368.	1.2	21
89	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
90	CD56 ^{bright} natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- <i>versus</i> -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. <i>Haematologica</i> , 2017, 102, 1936-1946.	1.7	20

#	ARTICLE	IF	CITATIONS
91	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 137, 983-993.	0.6	20
92	Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 648-655.	2.0	19
93	Immunosuppressive Therapy Without Hematopoietic Growth Factor Exposure in Pediatric Acquired Aplastic Anemia. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 469-478.	0.3	19
94	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458.	2.0	19
95	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-L). <i>Blood</i> , 2014, 124, 795-795.	0.6	19
96	New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. <i>Bone Marrow Transplantation</i> , 2014, 49, 1259-1265.	1.3	18
97	Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. <i>Blood Advances</i> , 2022, 6, 746-749.	2.5	18
98	Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. <i>Expert Review of Hematology</i> , 2010, 3, 731-742.	1.0	17
99	Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. <i>Journal of Pediatrics</i> , 1997, 130, 467-470.	0.9	16
100	Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 571884.	2.2	16
101	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	0.6	16
102	Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B cell precursor acute lymphoblastic leukemia. <i>European Journal of Immunology</i> , 2015, 45, 1980-1990.	1.6	15
103	Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811769033.	0.6	15
104	Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. <i>Blood</i> , 2014, 124, 38-38.	0.6	15
105	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides. <i>Blood</i> , 2006, 108, 1868-1868.	0.6	15
106	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
107	Metabolomic identification of α -ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. <i>Blood</i> , 2022, 139, 287-299.	0.6	14
108	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	2.5	13

#	ARTICLE	IF	CITATIONS
109	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
110	How we approach Philadelphia chromosome \hat{c} positive acute lymphoblastic leukemia in children and young adults. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28543.	0.8	13
111	The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 448-451.	0.6	13
112	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	0.6	13
113	Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias. <i>Medical and Pediatric Oncology</i> , 2001, 37, 415-416.	1.0	12
114	Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD. <i>Blood</i> , 2018, 131, 2863-2866.	0.6	12
115	The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 468-481.	0.3	12
116	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
117	Generic formulations of imatinib for treatment of Philadelphia chromosome \hat{c} positive leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27431.	0.8	11
118	The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2019, 70, 1-9.	0.2	11
119	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. <i>Blood</i> , 2012, 120, 359-359.	0.6	11
120	Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. <i>Bone Marrow Transplantation</i> , 1996, 18, 625-31.	1.3	11
121	The pharmacokinetics of oral cyclosporin a (neoral) during the first month after bone marrow transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 1668-1670.	0.3	10
122	HLA-DM expression is elevated in ETV6 \hat{c} AML1 translocation-positive pediatric acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2006, 30, 487-489.	0.4	10
123	Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. <i>Bone Marrow Transplantation</i> , 2018, 53, 1263-1269.	1.3	10
124	Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 321-327.	2.0	10
125	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1790-1795.	2.0	9
126	Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies. <i>Pediatric Clinics of North America</i> , 2015, 62, 257-273.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). <i>Blood</i> , 2013, 122, 543-543.	0.6	9
128	Heterodimer-Specific Stimulation Of Toll-Like Receptor 2 Induces Divergent Downstream Effects In Primary Samples Of Precursor B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3918-3918.	0.6	9
129	Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. <i>Blood</i> , 1995, 86, 4344-52.	0.6	9
130	Functional hyposplenism after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1343-1347.	1.3	8
131	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
132	Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2017, 13, 497-505.	0.8	8
133	Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky079.	1.4	8
134	Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 438-444.	2.0	8
135	Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss.. <i>Blood</i> , 2009, 114, 8-8.	0.6	8
136	Detection of T-Cells Specific for Leukemia-Associated Antigens in Pediatric Patients with Acute Lymphoblastic Leukemia in First Complete Remission.. <i>Blood</i> , 2004, 104, 526-526.	0.6	8
137	Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). <i>Haematologica</i> , 2022, 107, 2295-2303.	1.7	8
138	Pathophysiology of Chronic Graft versus Host Disease. , 0, , 17-30.		7
139	Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1172-1178.	2.0	7
140	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012, 120, 137-137.	0.6	7
141	Multiple Breath Washout Testing to Identify Pulmonary Chronic Graft Versus Host Disease in Children After Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 328.e1-328.e7.	0.6	7
142	Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031. <i>Bone Marrow Transplantation</i> , 2010, 45, 1653-1657.	1.3	6
143	STAT3 mutations and persistence of autoimmunity. <i>Blood</i> , 2013, 122, 2295-2296.	0.6	6
144	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury. <i>Kidney360</i> , 2022, 3, 37-50.	0.9	6
146	Bone pain caused by isolated paraspinal extramedullary relapse of childhood acute lymphoblastic leukemia. , 1999, 33, 113-115.		5
147	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. <i>Leukemia and Lymphoma</i> , 2021, 62, 2193-2201.	0.6	5
148	Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).. <i>Blood</i> , 2004, 104, 519-519.	0.6	5
149	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015, 126, 807-807.	0.6	5
150	Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 288-296.	0.3	4
151	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. <i>Blood</i> , 2012, 120, 470-470.	0.6	4
152	Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONCO51 Study. <i>Blood</i> , 2013, 122, 919-919.	0.6	4
153	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	0.6	4
154	Quantitation of Human Cells that Produce Neutrophils and Platelets in Vivo Obtained from Normal Donors Treated with Granulocyte Colony-Stimulating Factor and/or Plerixafor. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1945-1952.	2.0	3
155	A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 709-709.	0.6	3
156	Is Any Donor Too Old?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2-3.	2.0	2
157	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
158	Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28574.	0.8	2
159	Successful rescue transplant for children with primary graft failure using early intervention with a single day preparative regimen and related haploidentical donor. <i>Bone Marrow Transplantation</i> , 2021, 56, 2031-2033.	1.3	2
160	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2009, 114, 2606-2606.	0.6	2
161	What Is the Role of HSCT in Philadelphia-Chromosome-Positive and Philadelphia-Chromosome-Like ALL in the Tyrosine Kinase Inhibitor Era?. <i>Frontiers in Pediatrics</i> , 2021, 9, 807002.	0.9	2
162	Increased TLR9 Responses in B Cells at the Onset of Chronic GVHD. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 468.	0.3	1

#	ARTICLE	IF	CITATIONS
163	Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28263.	0.8	1
164	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2008, 112, 911-911.	0.6	1
165	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. <i>Blood</i> , 2011, 118, 837-837.	0.6	1
166	Circulating Angiogenic Factors As Biomarkers of Acute Gvhd Onset and Response to Therapy: Repair and Regeneration Versus Endothelial Damage and Inflammation. <i>Blood</i> , 2014, 124, 2489-2489.	0.6	1
167	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. <i>Blood</i> , 2016, 128, 1231-1231.	0.6	1
168	An Exaggerated B Cell CpG Response in Human Chronic Graft-versus-Host Disease: A Potential Mechanism and Biomarker for Diagnosis of Chronic GVHD.. <i>Blood</i> , 2004, 104, 4966-4966.	0.6	1
169	The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation.. <i>Blood</i> , 2009, 114, 2280-2280.	0.6	1
170	Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. <i>Blood</i> , 2019, 134, 875-875.	0.6	1
171	Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTc 1202 Study. <i>Blood</i> , 2020, 136, 11-12.	0.6	1
172	Inhibition of Cathepsin S Alters the T Cell Response to Minor Histocompatibility Antigens. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 461-462.	0.3	0
173	Too stressed for tests? Challenges of diagnosing psychological distress in pediatric cancer patients and survivors. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 123-124.	0.3	0
174	Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 417-419.	0.3	0
175	Chronic Graft-Versus-Host Disease after Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplantation. A Pediatric Blood and Marrow Transplant Consortium Study... <i>Blood</i> , 2007, 110, 4984-4984.	0.6	0
176	Impact of Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTc) Study. <i>Blood</i> , 2008, 112, 3006-3006.	0.6	0
177	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. <i>Blood</i> , 2009, 114, 2634-2634.	0.6	0
178	Therapeutic Potential for Toll-Like Receptor 2 Agonists In Pediatric Acute Lymphoblastic Leukemia (pre-B ALL): Induction of Apoptosis and Anti-ALL Immunogenicity. <i>Blood</i> , 2010, 116, 870-870.	0.6	0
179	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. <i>Blood</i> , 2012, 120, 467-467.	0.6	0
180	Functional Hyposplenism in Pediatric Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2012, 120, 4493-4493.	0.6	0

#	ARTICLE	IF	CITATIONS
181	YB-1 Is Activated by IL-7 and Is Overexpressed in Pediatric Pre-B Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1468-1468.	0.6	0
182	Higher Proportions of IFN γ -Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group O601 Randomized, Phase III Trial. Blood, 2012, 120, 1944-1944.	0.6	0
183	Prior Granulocyte Colony-Stimulating Factor Treatment Enhances the Immediate and Transient Output of Primitive Hematopoietic Cells in the Blood of Normal Adult Human Donors Treated with Plerixafor. Blood, 2014, 124, 5787-5787.	0.6	0
184	Provincial Disparities in Access to Allogeneic Transplant in Canada. Blood, 2018, 132, 4742-4742.	0.6	0
185	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. Blood, 2018, 132, 659-659.	0.6	0
186	Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. , 2022, , 405-430.		0
187	Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?. Frontiers in Pediatrics, 2022, 10, 796994.	0.9	0
188	236 Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. Journal of Clinical and Translational Science, 2022, 6, 37-38.	0.3	0